Table 1.

Summary of clinical data of the Puerta de Hierro (PdH) cohort.

Clinical variable	N	Categories	N	Percentage
Sex	84	Male	46	54.8
		Female	38	45.2
Age	83	≥ 60	47	56.7
		< 60	36	43.4
ECOG	78	0	28	36.8
		1	29	38.2
		2	18	23.7
		3	3	3.9
		4	0	0
		5	0	0
Stage	81	I	6	7.8
		II	23	29.9
		III	31	40.3
		IV	31	40.3
IPI	83	Low	28	33.7
		Low-Intermediate	23	27.7
		High-Intermediate	18	21.7
		High	14	16.9
Treatment	84	R-CHOP	76	90.5
		R-like	8	9.5
Response to treatment	83	Complete response	66	79.5
		Partial response	6	7.2
		No response	11	13.3
Refractory/Relapse	84	Refractory/Relapse	34	40.5
		No relapse	50	59.5
Status	84	Exitus	33	39.3
		Alive	51	60.7
COO (Lymph2Cx)	54	GCB	29	53.7
		ABC	14	25.9
		Unclassified	11	20.4
COO (Hans)	65	GCB	33	50.8
		Non-GCB	32	49.2
FISH		BLC2	11/50	22.0
		BCL6	18/45	40.0
		MYC	5/49	10.2
		Double-HIT	2/44	4.5

International Prognostic Index (IPI), rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), rituximab-like (R-like), cell of origin (COO), activated B-cell (ABC), germinal center B-cell (GCB), fluorescence in situ hybridization (FISH).